Search results for "Antiandrogen"

showing 10 items of 28 documents

Cutaneous manifestations of polycystic ovary syndrome

2020

Abstract Hirsutism, acne, and/or female pattern hair loss are common cutaneous manifestations of polycystic ovary syndrome (PCOS). However, while hirsutism is mainly related to androgen excess, both acne and female pattern hair loss may often depend on cutaneous alterations that are not linked to hyperandrogenism or increased androgen sensitivity. Because both acne and female pattern hair loss cannot be considered a sign of hyperandrogenism, neither should be included in the diagnostic process of PCOS without demonstration of increased levels of circulating androgens. In addition, in patients with androgen-dependent acne, the concomitant proliferation of Propionibacterium acnes in skin may …

0301 basic medicinemedicine.medical_specialtyintegumentary systembiologybusiness.industrymedicine.drug_classEndocrinology Diabetes and MetabolismHyperandrogenism030209 endocrinology & metabolismmedicine.diseaseAndrogen ExcessAntiandrogenbiology.organism_classificationPolycystic ovaryDermatology03 medical and health sciencesPropionibacterium acnes030104 developmental biology0302 clinical medicineHair lossmedicinebusinessAcnehirsutismCurrent Opinion in Endocrine and Metabolic Research
researchProduct

A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer

2017

Crosstalk between the androgen receptor (AR) and other signaling pathways in prostate cancer (PCa) severely affects the therapeutic outcome of hormonal therapy. Although anti-androgen therapy prolongs overall survival in PCa patients, resistance rapidly develops and is often associated with increased AR expression and upregulation of the HER2/3-AKT signaling pathway. However, single agent therapy targeting AR, HER2/3 or AKT usually fails due to the reciprocal feedback loop. Previously, we reported that wedelolactone, apigenin, and luteolin are the active compounds in Wedelia chinensis herbal extract, and act synergistically to inhibit the AR activity in PCa. Here, we further demonstrated th…

0301 basic medicinenatural productsmedicine.drug_classPharmacologyurologic and male genital diseasesAntiandrogen03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineHER3HER2LNCaPMedicineEnzalutamidePharmacology (medical)Pharmacologybusiness.industrylcsh:RM1-950apoptosisprostate cancerWedelolactonemedicine.diseaseAndrogenanimal modelsAndrogen receptorlcsh:Therapeutics. Pharmacology030104 developmental biologychemistry030220 oncology & carcinogenesisHormonal therapybusinessFrontiers in Pharmacology
researchProduct

Testosterone-Lowering Medication and Its Association With Recidivism Risk in Individuals Convicted of Sexual Offenses

2020

For a particular subgroup of individuals with severe paraphilic disorders and a high risk of sexual recidivism, the combination of sex drive–reducing medications and psychotherapy is a promising treatment approach. The present quasi-experimental study aims at comparing differences in clinical characteristics and dynamic risk factors between persons receiving (+TLM, n = 38) versus not receiving (−TLM, n = 22) testosterone-lowering medications (TLMs). Individuals receiving TLM were more frequently diagnosed with paraphilic disorders. Neither the criminal history nor average risk scores differed between the two groups. In the +TLM, Stable-2007 scores showed a stronger decrease after TLM treat…

AdultMaleantiandrogensTreatment durationPsychopathySelf-ControlRisk FactorsGermanyparaphilic disordermedicineHumansTestosteroneAssociation (psychology)General PsychologyAgedAverage riskDuration of TherapyRecidivismParaphilic DisordersSex Offensesrisk assessmentAndrogen Antagonistssexual offender treatmentTestosterone (patch)ArticlesCriminalsMiddle Agedmedicine.diseaseGnRH-agonistsCriminal historyPsychotherapyPsychiatry and Mental healthTreatment OutcomeRecidivismRisk assessmentPsychologyClinical psychologySexual Abuse
researchProduct

Evidence for increased androsterone metabolism in some normoandrogenic women with acne.

1993

Increased androgen production from the ovary, adrenal or locally in skin has been implicated in the pathogenesis of acne. Recent data have provided evidence that androsterone (Ao) metabolism is exaggerated in acne and serum metabolites of Ao differentiate between acne and hirsutism in hyperandrogenic women. Here we have extended these studies to normoandrogenic women who have moderate to severe acne. We measured serum ovarian and adrenal androgens as well as the glucuronide and sulfate metabolites of Ao and 3 alpha-androstanediol which reflect, in part, peripheral androgen action. In a group of 15 well-selected normoandrogenic patients with acne, both serum Ao glucuronide (G) and Ao were el…

Adultmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryBiologyAntiandrogenAndrosteroneBiochemistryPathogenesischemistry.chemical_compoundEndocrinologyReference ValuesInternal medicineAcne VulgarismedicineHumanshirsutismAcneAndrosteroneBiochemistry (medical)medicine.diseaseAndrogenEndocrinologymedicine.anatomical_structurechemistryAndrogensFemaleGlucuronideThe Journal of clinical endocrinology and metabolism
researchProduct

Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.

1991

Hirsutism in women is often explained on the basis of abnormal peripheral androgen metabolism. To determine whether serum markers of ovarian, adrenal, or peripheral androgen production may be helpful determinants in the treatment of hirsutism and to compare the efficacy of treatment with dexamethasone or spironolactone, 20 hyperandrogenic hirsute patients were treated for up to 2 years. Eleven women who were selected on the basis of sensitivity to dexamethasone were treated with a daily dose of 0.37 mg dexamethasone and had androgen levels suppressed into the normal range. Although significant (P less than .05), Ferriman-Gallwey scores decreased only by 20%: 14.2 +/- 0.5 to 11.4 +/- 0.6. Ni…

Adultmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classmedicine.medical_treatmentSpironolactoneAndrogen suppressionAntiandrogenAndrosteroneDexamethasonechemistry.chemical_compoundInternal medicinemedicineHumansTestosteronehirsutismDexamethasoneChemotherapybusiness.industryDehydroepiandrosterone SulfateAndrostenedioneObstetrics and GynecologyAndrogen AntagonistsDihydrotestosteroneGeneral MedicineDehydroepiandrosteroneAndrogenmedicine.diseaseAndrostane-317-diolDrug CombinationsEndocrinologychemistrySpironolactoneAndrogensCorticosteroidFemalebusinessmedicine.drugObstetrics and gynecology
researchProduct

Treatment of hyperandrogenic alopecia in women

2003

Many women with androgenic alopecia have normal circulating androgen levels. Increased scalp sensitivity to androgens may account for these cases. Even when androgen levels are increased, no particular pattern has emerged. Classical anti-androgen measures have proved disappointing, in contrast to the results obtained in women with hirsutism or acne. This study evaluated flutamide and finasteride in 36 premenopausal, hyperandrogenic women presenting with androgenic alopecia. Frontal hair thinning was assessed in photos of the frontoparietal region using the Ludwig grading system. Thirty ovulatory women matched for age and body weight served as a control group. Groups of 12 subjects received …

Adultmedicine.medical_specialtyRandomizationmedicine.drug_classDehydroepiandrosteroneEthinyl EstradiolAntiandrogenFlutamidelaw.inventionchemistry.chemical_compound5-alpha Reductase InhibitorsRandomized controlled triallawInternal medicineHumansMedicineTestosteroneEnzyme InhibitorsCyproterone AcetateTestosteronehirsutismGynecologyDehydroepiandrosterone Sulfatebusiness.industryFinasterideHyperandrogenismObstetrics and GynecologyCyproterone acetateAlopeciaAndrogen AntagonistsGeneral MedicineAndrogenmedicine.diseaseFlutamideRegimenEndocrinologyHair lossItalyLiverReproductive MedicinechemistryFinasterideCyproteroneFemaleHyperandrogenismbusinessmedicine.drugFertility and Sterility
researchProduct

APPROCCIO FARMACOLOGICO NEL PAZIENTE CON MALATTIA NON SUSCETTIBILE DI TERAPE LOCO-REGIONALI AD INTENTO CURATIVO.

2006

CARCINOMA PROSTATICO AVANZATO ORMONOTERAPIA ANALOGHI LHRH ANTIANDROGENI TERAPIA IMMEDIATA O RITARDATA TERAPIA INTERMITTENTESettore MED/24 - Urologia
researchProduct

Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single-b…

2021

Background Acne is a chronic inflammatory skin disease which involves the pilosebaceous unit. Tissue inflammation isone of the crucial mechanisms, amongst others. Of the various cytokines, leukotriene B4 (LT-B4) is the most potentleucocyte chemotactic mediator. Montelukast is an antagonist of the LT-B4 receptor. Finasteride is an antiandrogen whichspecifically inhibits the 5α-reductase enzyme. Aims This study aimed at comparing the efficacy, tolerability and safety of montelukast versus finasteride in the treatmentof moderate acne in women. Patients/method This randomized, single-blinded, prospective trial over 12 weeks recruited 65 female subjects with moderate acne vulgaris (Global Acne G…

Cyclopropanesmedicine.medical_specialtymedicine.drug_classDermatologyAcetatesSulfidesAntiandrogenGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineAcne VulgarismedicineHumansProspective StudiesAdverse effectAcneMontelukastbusiness.industryFinasterideAntagonistmedicine.diseasechemistryTolerabilityFinasterideQuinolinesFemalebusinessmedicine.drugJournal of cosmetic dermatologyREFERENCES
researchProduct

Pharmacological treatment of patients with paraphilic disorders and risk of sexual offending: An international perspective

2017

Objectives: The present study aims to evaluate existing policy and practice relating to the use of pharmacological treatments with patients suffering from paraphilic disorders who are at risk of committing further sexual offences. Methods: A systematic literature search was conducted to document current legal policies across 26 different countries. In addition, a questionnaire assessing the practice of pharmacological treatment was sent to practitioners involved in the treatment of patients with paraphilic disorders. Results: Legal policies concerning the preconditions of using pharmacological treatments differ considerably between countries, and for most jurisdictions do not exist. Drawing…

MaleInternationalityPsychotherapistParaphilic DisordersAntiandrogensbusiness.industryHealth PolicySexual BehaviorSex OffensesPerspective (graphical)030227 psychiatryPharmacological treatmentAndrogen deprivation therapy03 medical and health sciencesPsychiatry and Mental healthL990 Social studies not elsewhere classified0302 clinical medicineDrug TherapyPractice Guidelines as TopicHumansMedicinebusinessSocial psychologyBiological PsychiatryParaphilic DisordersThe World Journal of Biological Psychiatry
researchProduct

Antiandrogens alone or in combination for treatment of prostate cancer: The European experience

1989

Abstract In Europe, antiandrogens have been used for many years to treat prostate cancer, either as monotherapy or as part of a “combination therapy” with either surgical or chemical castration. However, considerable debate still exists regarding the relative benefits of combination therapy versus antiandrogen monotherapy or castration alone. This article reviews the European experience with antiandrogen therapy, including the personal experiences of the authors.

MaleOncologymedicine.medical_specialtyCombination therapyAntiandrogensmedicine.drug_classUrologyurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAntiandrogen TherapyChemical castrationRandomized Controlled Trials as TopicGynecologybusiness.industryProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseCombined Modality TherapyFlutamideEuropeCastrationchemistrybusinessOrchiectomyhormones hormone substitutes and hormone antagonistsUrology
researchProduct